Abstract
Asbestos is a recognized high-profile health hazard with an estimated total cancer burden from malignant mesothelioma and lung cancer in industrialized countries to be in the order of 30,000 cancers per year (Tossavainen A, People Work Res Rep. 14: 8–27, 1997) with further deaths related to lung fibrosis (asbestosis) and complications of asbestos-related diffuse pleural thickening. Projections for the 1995–2029 period suggest that male mesothelioma deaths will double over the next 20 years to a peak of 9,000 in 2018 and then decline, with an estimated 250,000 deaths up to 2025 in Europe (Peto J, Decarli A, La Vecchia C et al.. Br J Cancer. 79: 666–72, 1999).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tossavainen A. Asbestos, asbestosis and cancer: exposure criteria for clinical diagnosis. People Work Res Rep. 1997;14:8–27. Helsinki: Finnish Institute of Occupational Health.
Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–72.
Willis RA. Pathology of tumors. Washington, DC: Butterworth; 1960. 185.
Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317–31.
Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma. Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol. 1988;6:147–53.
Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718–21.
La Vecchia C, Boffetta P. Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma. Eur J Cancer Prev. 2012;21(3):227–30.
La Dou J. The asbestos cancer epidemic. Environ Health Perspect. 2004;112:285–90.
Craighead JE, Gibbs AR, Pooley FD. Mineralogy of asbestos. In: Craighead JE, Gibbs AR, editors. Asbestos and its disease. New York: Oxford University Press; 2008. p. 23–38. Chapter 2.
Bartrip PW. History of asbestos-related disease. Postgrad Med J. 2004;80:72–6.
Browne K. Thresholds of risk. In: Gibbs GW, Dunnigan J, Kido M, Higashi T, editors. Health risks from exposure to mineral fibres. An international perspective. North York: Captus University Publications; 1991. p. 355.
Iwatsubo Y, Pairon JC, Boutin C, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case control study. Am J Epidemiol. 1998;148:133–42.
Gibbs AR, Pooley FD. Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax. 1990;45:649–54.
Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.
Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma; attributable risk of asbestos exposure. Occup Environ Med. 1994;51:804–11.
Roggli VL, Oury TD, Moffatt EJ. Malignant mesothelioma in women. Anat Pathol. 1997;2:147–63.
Xu Z, Armstrong BK, Blunsdon BJ, et al. Trends in mortality for malignant mesothelioma of the pleura, and production and use of asbestos in Australia. Med J Aust. 1985;143:185–7.
Andersson M, Olsen JH. Trend and distribution of mesothelioma in Denmark. Br J Cancer. 1985;51:699–705.
Mark EJ, Yokoi T. Absence of evidence for a significant background incidence of diffuse malignant mesothelioma from asbestos exposure. Ann N Y Acad Sci. 1991;643:196–204.
Peterson JT, et al. Non asbestos-related malignant mesothelioma: a review. Cancer. 1984;54:951.
Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med. 1996;30(3):252–66.
Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000;44(8):565–601.
Hodgson JT, et al. The expected burden of mesothelioma mortality in Great Britain from 2002–2050. Br J Cancer. 2005;92(3):587–93.
Berman DW, Crump KS. Final draft: technical support document for a protocol to assess asbestos related risk. US Environmental Protection Agency;2003.
Yarborough CM. Chrysotile as a cause of mesothelioma: an assessment based on epidemiology. Crit Rev Toxicol. 2006;36:165–87.
Stanton MF, Wrench C. Mechanisms of mesothelioma induction with asbestos and fibreglass. J Natl Cancer Inst. 1972;48:797.
Stanton MF, Layard M, Tegeris A, Miller E, May M, Morgan E, Smith A. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst. 1981;67:965–75.
Pott F, Huth F, Fredericks K. Tumorogenic effect of fibrous dust in experimental animals. Environ Health Perspect. 1974;9:313–5.
Davis JMG, Jones AD. Comparisons of the pathogenicity of long and short fibres of chrysotile asbestos in rats. Br J Exp Pathol. 1988;69:717–37.
Platek F, et al. Chronic inhalation of short asbestos fibres. Fundam Appl Toxicol. 1985;5:327–40.
Bernstein DM, et al. Comparison of Calidria chrysotile asbestos to pure tremolite: final results of the inhalation biopersistence and histopathology examination following short-term exposure. Inhal Toxicol. 2005;17(9):427–49.
Bernstein DM, Rogers RA, Sepulveda R, et al. Quantification of the pathological response and fate in the lung and pleura of chrysotile in combination with fine particles compared to amosite-asbestos following short-term inhalation exposure. Inhal Toxicol. 2011;23(7):372–91.
Higgins ITT, Glassman JH, Oh MS, et al. Mortality of reserve mining company employees in relation to taconite dust exposure. Am J Epidemiol. 1983;118(5):710–9.
McDonald JC, Gibbs GW, Liddell DK, et al. Mortality after long exposure to cummintonite-grunerite. Am Rev Respir Dis. 1978;118.
Report of Expert Panel on Health Effects of Asbestos and Synthetic Vitreous Fibres: the influence of fibre length. Agency for toxic substances and disease registry. Atlanta; 2003.
McDonald JC, et al. Mesothelioma and asbestos fibre type. Evidence from lung tissue analyses. Cancer. 1989;63(8):1544–7.
Rogers A, Leigh J, Berry G, Ferguson DA, Mulder HB, Ackad M. Relationship between lung asbestos fibre type and concentration and relative risk of mesothelioma. Cancer. 1991;67:1912–20.
Berman DW. Apples to apples: the origin and magnitude of differences in asbestos cancer risk estimates derived using varying protocols. Risk Anal. 2010;31:1539–6924.
Suzuki Y, Yuen SR. Asbestos tissue burden study on human malignant mesothelioma. Ind Health. 2001;39:150–60.
Suzuki Y, Yuen SR. Asbestos fibres continuing to the induction of human malignant mesothelioma. Ann N Y Acad Sci. 2002;982:160–76.
Chiappino G. Mesotelioma: Ruyolo Delle Fibre Ultrafini Aire Conseguenti Riflessi In: Campo Preventivo Aire Medico-Legale. Med Lab. 2005;96:3–23.
Dodson RF, O’Sullivan MF, Huang J, et al. Asbestos in extra-pulmonary sites – omentum and mesentery. Chest. 2000;117:486–93.
Boutin C, Dumortier P, Rey F, et al. Black spots concentration oncogenic asbestos fibres in the parietal pleura. Thoracoscopic and mineralogic study. Am J Respir Crit Care Med. 1996;153:444–9.
Ontario Royal Commission. The Royal Commission on Matters of Health and Safety Arising from the Use of Asbestos in Ontario. J. Stefan Dupre, J. Fraser Mustard, Robert J. Uffen. Ontario Ministry of the Attorney General. 1983 Three Volumes.
Craighead JE, Gibbs AR, Pooley FD. Mineralogy of asbestos. In: Craighead JC, Gibbs AR, editors. Asbestos and its diseases. Oxford: Oxford University Press; 2008. p. 23–38. Chapter 2.
Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44.
Roach HD, Davies GJ, Attanoos R, et al. Asbestos: when the dust settles – an imaging review of asbestos related disease. Radiographics. 2002;22:S167–84.
De Vuyst P, Karjalainen A, Dumortier P, et al. Guidelines for mineral fibre analysis in biological samples: report of the ERS Working Group. Eur Respir J. 1998;11:1416–26.
Holmes S. Developments in dust sampling and counting techniques in the asbestos industry. Ann N Y Acad Sci. 1965;132:288–97.
The Asbestos International Association. Reference method for the determination of airborne asbestos fibre concentrations at workplaces by light microscopy (membrane filter method). London: Asbestos International Association; 1979.
Walton WH. The natures hazards and assessment of occupational exposure to airborne asbestos dust: a review. Ann Occup Hyg. 1982;25:117–247.
Gibbs AR, Attanoos RL. Examination of lung specimens. J Clin Pathol. 2000;53:507–12.
Attanoos RL, Gibbs AR. An approach to industrial post mortems. Histopathology. 2009;54(1):134–42.
Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology. 2008;53(3):340–4.
Attanoos RL, Gibbs AR. Pseudomesotheliomatous’ carcinomas of the pleura – a 10 year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology. 2003;43(5):444–52.
Roggli VL, Gibbs AR, Attanoos RL, Churg A, Popper H, Cagle P, Corrin B, Franks T, Galateau-Salle F, Galvin J, Hasleton P, Henderson D, Honma K. Pathology of asbestosis – an update of the diagnostic criteria. Report of the Asbestosis Committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134:462–80.
Roggli VL. Chapter 3. In: Roggli VL, Oury TD, Sporn TA, editors. Asbestos bodies and nonasbestos ferruginous bodies pathology of asbestos associated diseases. 2nd ed. Verlag: Springer; 2004; p. 34–70.
Pooley FD, Ranson DL. Comparison of the results of asbestos fibre dust counts in lung tissue obtained by analytical electron microscopy and light microscopy. J Clin Pathol. 1986;39:313–7.
Christian A, Pooley FD, Attanoos RL, Gibbs AR. Lung mineral fibre analysis from a National Referral Centre of 402 cases and >4000 fibres – the Cardiff experience in 2006. J Pathol. 2009;221(S1):S8.
Tuomi T. Fibrous minerals in the lungs of mesothelioma patients; comparison between data on SEM, TEM and personal interview information. Am J Ind Med. 1992;21:155–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Attanoos, R.L. (2014). Malignant Mesothelioma: Asbestos Exposure. In: Anttila, S., Boffetta, P. (eds) Occupational Cancers. Springer, London. https://doi.org/10.1007/978-1-4471-2825-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2825-0_15
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2824-3
Online ISBN: 978-1-4471-2825-0
eBook Packages: MedicineMedicine (R0)